Upgrade for detailed insurance, legislation, and other documents analytics for individual cases; real-time analysis of the datasets from your EHR, CRM, ERP, or other software; and more Enterprise Features.
Oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage I (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9050
This HCPCS code reports the primary focus of an evaluation and management (E/M) visit for a cancer patient, including work-up, evaluation, or staging at diagnosis or recurrence.
2025 HCPCS code J9350
Injection, mosunetuzumab-axgb, 1 mg; a chemotherapy drug administered intravenously.
2025 HCPCS code G9051
This HCPCS code reports the primary focus of an evaluation and management (E/M) visit for a cancer patient, where the provider makes treatment decisions, discusses options, and manages cancer-directed therapy.
2025 HCPCS code G9078
Reports disease status of prostate cancer (limited to adenocarcinoma, T2 or T3a, Gleason 8-10, or PSA >20 at diagnosis) within a Medicare-approved demonstration project.
2025 HCPCS code G9096
Reports information on the disease status of a patient's esophageal cancer, specifically adenocarcinoma or squamous cell carcinoma, staged T1-T3, N0-N1 or NX, before neoadjuvant therapy, with no evidence of progression, recurrence, or metastasis (Medicare demonstration project).
2025 HCPCS code G9105
Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post r0 resection without evidence of disease progression, recurrence, or metastases.
2025 CPT code 0155U
PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis for breast cancer, using formalin-fixed paraffin-embedded breast tumor tissue, to detect mutations, reported as PIK3CA gene mutation status.
2025 HCPCS code G9117
This HCPCS code reports the disease status of ovarian cancer, specifically epithelial cancer with unknown progression extent, for a Medicare demonstration project (2006).
2025 HCPCS code G9090
Reports the disease status of a patient's rectal cancer, specifically limited invasive adenocarcinoma (T1-2, N0, M0) before neoadjuvant therapy, within a Medicare demonstration project.
2025 HCPCS code J9350
Tiêm, mosunetuzumab-axgb, 1 mg; một loại thuốc hóa trị tiêm tĩnh mạch.
Injektion, Mosunetuzumab-Axgb, 1 mg; ein intravenös verabreichtes Chemotherapeutikum.
2025 HCPCS code J9350
주사제, 모수네투주맙-axgb, 1 mg, 정맥 주사로 투여되는 화학 요법 약물.
2025 HCPCS code G9109
头颈部癌的疾病状态，仅限于以鳞状细胞为主要细胞类型的口腔癌、咽癌和喉癌，未显示疾病进展。
2025 HCPCS code G9078
يُبلغ عن حالة مرض سرطان البروستاتا (يقتصر على السرطان الغدي أو T2 أو T3a أو Gleason 8-10 أو <a href="../medical-coding/reference/PSA" target="_blank" title="Medical Code PSA 2025">PSA</a> > 20 عند التشخيص) ضمن مشروع تجريبي معتمد من Medicare.
2025 HCPCS code G9137
Oncology; disease status; Non-Hodgkin’s lymphoma, any cellular classification; relapsed/refractory (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9068
Oncology disease status limited to small cell and combined small cell/non-small cell; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9125
Oncology disease status of chronic myelogenous leukemia (CML), limited to Philadelphia chromosome positive and/or BCR-ABL positive, blast phase not in hematologic, cytogenetic, or molecular remission. For use in a Medicare-approved demonstration project.
2025 CPT code 0006M
mRNA expression profiling of 161 genes and alpha-fetoprotein levels in hepatocellular carcinoma tissue; algorithmic risk classification.
2025 CPT code 0422U
Analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, comparing it to a baseline test via next-generation sequencing; algorithm reports quantitative change from baseline.
2025 CPT code 0334U
Targeted genomic sequencing analysis of formalin-fixed paraffin-embedded (FFPE) solid tumor tissue DNA, examining 84 or more genes for variants, copy number changes, rearrangements, microsatellite instability, and tumor mutational burden.
2025 CPT code 0359U
Analysis of all prostate-specific antigen (PSA) structural isoforms using phase separation and immunoassay; plasma; algorithm reports cancer risk.
2025 CPT code 0113U
Measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum, following prostatic massage, using RNA amplification and fluorescence-based detection; algorithm reported as a risk score.
2025 CPT code 0362U
Gene expression profiling of 82 genes and 10 housekeeping genes via RNA sequencing from a fine needle aspirate or FFPE tissue specimen of papillary thyroid cancer, with algorithmic analysis classifying the molecular subtype and recurrence risk.
2025 CPT code 0421U
This code represents a fecal-based colorectal cancer screening test that analyzes the expression of eight genes and fecal hemoglobin, providing a positive or negative risk assessment for colorectal cancer.
2025 CPT code 0245U
Thyroid oncogene panel analysis using next-generation sequencing (NGS) to assess malignancy risk in indeterminate thyroid fine needle aspiration (FNA) specimens.
2025 CPT code 0019U
RNA gene expression analysis using whole transcriptome sequencing on formalin-fixed paraffin-embedded or fresh frozen tumor tissue; predictive algorithm reported as potential targets for therapeutic agents.
2025 CPT code 0211U
Next-generation sequencing (NGS) analysis of DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue; identifies variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapeutic associations.
2025 CPT code 0248U
Predicts brain or brain metastasis tumor response to twelve drugs using a 3D spheroid cell culture.
2025 CPT code 0356U
Evaluates cell-free DNA from oropharyngeal or anal specimens for 17 DNA biomarkers associated with HPV-related cancer; algorithmic analysis determines cancer recurrence likelihood.
2025 CPT code 0244U
Comprehensive genomic profiling of solid tumor tissue using next-generation sequencing (NGS) to analyze 257 genes for variations.
2025 CPT code 0083U
Oncology; response to chemotherapy drugs using motility contrast tomography of fresh or frozen tissue; reported as likelihood of sensitivity or resistance to drugs or drug combinations.
2025 CPT code 0315U
mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping) in formalin-fixed paraffin-embedded (FFPE) tissue from cutaneous squamous cell carcinoma (SCC), providing a categorical risk assessment (Class 1, 2A, 2B).
2025 CPT code 0342U
Multiplex immunoassay for pancreatic cancer markers in serum; diagnostic algorithm reported qualitatively.
2025 CPT code 0340U
Analysis of minimal residual disease (MRD) in plasma, personalized to each patient based on prior next-generation sequencing of tumor and germline DNA; reported as absence or presence of MRD, with disease-burden correlation if applicable.
2025 CPT code 0564T
This CPT code reports a drug-response assay evaluating the effectiveness of at least 14 chemotherapy drugs or combinations on cultured cancer stem cells and bulk tumor cells from a fresh tumor biopsy.
2025 CPT code 0391U
Next-generation sequencing (NGS) analysis of DNA and RNA from formalin-fixed paraffin-embedded (FFPE) solid tumor tissue, encompassing 437 genes, with an interpretive report for various genetic alterations and an algorithm-generated immunotherapy response score.
2025 CPT code 0317U
Four-probe fluorescence in situ hybridization (FISH) assay of whole blood to evaluate lung cancer risk in patients with indeterminate lung nodules.
2025 HCPCS code G9132
Oncology - Other
2025 HCPCS code G9136
Disease status of non-Hodgkin’s lymphoma with transformation of cell type from one classification to another (Used in a Medicare demonstration project in 2006).
2025 HCPCS code G9102
Oncology; disease status; gastric cancer, limited to adenocarcinoma, clinical or pathologic M0, unresectable with no evidence of disease progression (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9126
Chronic Myelogenous Leukemia, positive for Philadelphia chromosome or BCR/ABL gene, in remission.
2025 HCPCS code G9109
Disease status of head and neck cancer, limited to cancers of the oral cavity, pharynx, and larynx with squamous cell as the predominant cell type, showing no disease progression.
2025 HCPCS code G9069
Oncology - disease status; small cell lung cancer (limited to small cell and combined small cell/non-small cell); extensive stage at diagnosis, metastatic, locally recurrent, or progressive. For use in a Medicare-approved demonstration project.
2025 HCPCS code G9103
Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project).
Continue with Personal Account
Thank you for exploring iFrame ♥ Please subscribe for unlimited access to our top-tier AI model, which directly supports our dedicated knowledge creators maintaining an ad-free internet experience.